<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000045454"><TermName>denileukin diftitox</TermName><TermPronunciation>(DEH-nih-LOO-kin DIF-tih-tox)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat cutaneous T-cell lymphoma that can bind the cytokine IL-2  and that has not responded to other treatment. It is also being studied in the treatment of other types of cancer. Denileukin diftitox is made by combining a part of IL-2 with a bacterial toxin. The IL-2 part of the drug attaches to the cancer cells and then the toxin kills the cells. Denileukin diftitox is a type of immunotoxin and a type of fusion toxin.  Also called Ontak.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000705485" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;denileukin diftitox&quot;" language="en" id="_3"/><MediaLink ref="CDR0000705484" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;denileucina diftitox&quot;" language="es" id="_4"/><SpanishTermName>denileucina diftitox</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar el linfoma cutáneo de células T  que se puede unir a la citocina IL-2 y que no respondió a otro tratamiento.   También está en estudio para el tratamiento de otros tipos de cáncer. La denileucina diftitox se elabora combinando una parte de la IL-2 con una toxina bacteriana.   La parte de IL-2 del medicamento se adhiere a las células cancerosas y luego la toxina las destruye.  La denileucina diftitox es un tipo de inmunotoxina y un tipo de toxina de fusión. También se llama Ontak.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateLastModified>2009-07-21</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000669854">Denileukin Diftitox</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
